{"schema_version":"secwatch.filing_event.v1","accession":"0001658247-26-000052","form_type":"8-K","ticker":"CRNX","cik":"0001658247","company_name":"Crinetics Pharmaceuticals, Inc.","filed_at":"2026-08-03T20:09:02+00:00","discovered_at":"2026-08-03T20:10:00.328185+00:00","generated_at":"2026-08-03T20:10:07.498662+00:00","sec_items":["2.02","9.01"],"event_type":"m_and_a","sentiment":"positive","materiality_score":1.0,"calibrated_materiality_score":1.0,"confidence":"high","headline":"Vertex to acquire Crinetics for $85/share (~$10B equity value); Q2 PALSONIFY revenue $24M","bullets":["Vertex to acquire Crinetics for $85.00 per share cash, total equity value ~$10.0B (~$8.8B net of cash).","Transaction approved by both boards, expected to close Q3 2026 subject to regulatory and stockholder approvals.","Q2 2026 net product revenue from PALSONIFY $24.0M, up from $10.3M in Q1 2026.","Net loss $120.9M for Q2 2026 vs $115.6M in Q2 2025.","Cash and investments $1.2B as of June 30, 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001658247-26-000052","json":"https://secwatch.observer/filing/0001658247-26-000052.json","markdown":"https://secwatch.observer/filing/0001658247-26-000052.md","text":"https://secwatch.observer/filing/0001658247-26-000052.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1658247/000165824726000052/0001658247-26-000052-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1658247/000165824726000052/crnx-20260803.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-08-03T20:10:07.498662+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}